This is a summary of the European public assessment report (EPAR) for Brilique. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Brilique.
Therapeutic Indication
Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with * acute coronary syndromes (ACS) or * a history of myocardial infarction (MI) and a high risk of developing an atherothrombotic event Brilique, co\-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.
Therapeutic Area (MeSH)
ATC Code
B01AC24
ATC Item
N/A
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
INN / Common Names
EMA Name
Brilique
Medicine Name
Brilique
Aliases
N/ANo risk management plan link.
